Rovamycine Tablet

Susceptible infections, Cryptosporidiosis, Toxoplasmosis, Protozoal infections

Oral Toxoplasmosis; Protozoal infections; Cryptosporidiosis; Susceptible infections Adult: 6-9 million units/day in 2-3 divided doses, increased to 15 million units/day, given in divided doses for severe infections.

Oral Child and Neonates: Chemoprophylaxis of congenital toxoplasmosis: 50 mg/kg bid.

May be taken with or without food.

Hypersensitivity.

Hepatic impairment; pregnancy and lactation. Monitor liver function. History of arrhythmias or predisposition to QT interval prolongation.

C

Decreases carbidopa absorption and levodopa concentrations. Increased risk of ventricular arrhythmias when used with astemizole, cisapride and terfenadine. Risk of acute dystonia when used with fluphenazine.

Nausea, vomiting, abdominal pain, diarrhoea; urticaria, pruritus, macular rashes. Transient paraesthesia may occur. Potentially Fatal: Pseudomembranous colitis; anaphylaxis; neuromuscular blockade; ventricular arrhythmias, prolongation of QT interval.

Spiramycin is a macrolide antibacterial that inhibits protein synthesis by irreversibly binding to the 50S subunit of the ribosomal subunit thus blocking the transpeptidation or translocation reactions of susceptible organisms resulting in stunted cell growth

Rovamycine 3 MIU Tablet manufactured by Synovia Pharma PLC. Its generic name is Spiramycine.